Zacks Analyst Blog Highlights Costco Wholesale, AstraZeneca, Medtronic, Sony Group and Applied Materials

0

For immediate release

Chicago, IL – April 11, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include Costco Wholesale Corp. COST, AstraZeneca PLC AZN, Medtronic plc MDT, Sony Group Corp. SONY and Applied Materials, Inc. AMAT.

Here are highlights from Friday’s analyst blog:

Top Inventory Reports for Costco, AstraZeneca and Medtronic

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., AstraZeneca PLC and Medtronic plc. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.

You can see all today’s research reports here >>>

Shares of Costco outperformed the industry Zacks Retail – Discount Stores over the past year (+69.5% vs. +23.7%), reflecting the company’s growth strategies, better pricing management, a trend of membership and growing penetration of e-commerce business. The strategy of selling products at discount prices has helped attract customers looking for value and convenience. These factors contributed to recording impressive sales and profit figures.

Costco had a decent performance in the second quarter of fiscal 2022, where both top and bottom results improved year over year. Additionally, Costco has witnessed a stellar comp sales run. While the aforementioned factors cause optimism. However, supply chain bottlenecks and rising labor and freight costs remain concerns. Any deleveraging of the SG&A rate can hurt margins.

(You can read the full Costco research report here >>>)

Shares of Astra Zeneca have outperformed the industry Zacks Large Cap Pharmaceuticals over the past year (+47% vs. +38.5%). The Zacks analyst believes that the company’s new drugs, primarily cancer drugs, Lynparza, Tagrisso and Imfinzi should continue to generate revenue. Its pipeline is strong with multiple Phase III data reads lined up. AstraZeneca has also engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in high-growth geographies like emerging markets. Cost reduction efforts should boost profits.

The acquisition of Alexion strengthens its immunology franchise, adding several drugs that can increase its turnover. However, AstraZeneca’s diabetes franchise faces fierce competition as pricing pressure hurts sales in the respiratory unit. Sales of certain drugs are suffering from COVID-19. Sales are slowing in key markets, China, due to price pressure.

(You can read the full research report on AstraZeneca here >>>)

Shares of Medtronic have outperformed the industry Zacks Medical – Products over the period since the beginning of the year (+9.3% against -7.3%). Medtronic recorded organic growth in the Cardiovascular, Neuroscience and Diabetes segments. The company claims market share gains in 60% of its business.

However, the revenue sluggishness reflects the adverse impact of COVID-19 on the market and labor shortages in the healthcare system. CRDN sales were down mid-single digit, given the impact of COVID-19 on PCI procedures. In addition, there have been low double-digit organic declines in RGR, with ventilator sales declining into the 1950s as demand returns to pre-pandemic levels.

(You can read the full Medtronic research report here >>>)

Other noteworthy reports we feature today include Sony Group Corp. and Applied Materials, Inc.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations climbed +143.0%, +175.9%, +498 .3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Medtronic PLC (MDT): Free Inventory Analysis Report

Costco Wholesale Corporation (COST): Free Inventory Analysis Report

Applied Materials, Inc. (AMAT): Free Inventory Analysis Report

Sony Corporation (SONY): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Share.

Comments are closed.